The cardiolipin-targeting peptide SS-31/elamipretide became the first approved therapy for Barth syndrome, based on >45% improvement in knee extensor muscle strength in the Phase 2 TAZPOWER trial — a landmark for the whole mitochondrial-peptide class.
Read source →A widely-read explainer on how glucose tolerance and mitochondrial energy output decline with age, and the practical levers (diet, exercise, sleep) with the most human evidence behind them for preserving metabolic health.
Read source →Mitrix Bio is manufacturing donor mitochondria in bioreactors and infusing them into paying patients at Right to Try clinics in Texas, California, and Florida — including a 91-year-old physicist as one of its first two patients. No peer-reviewed efficacy data exists yet. Included as a development worth watching, not a recommendation — this is an unregulated, direct-to-consumer offering with an N of 2.
Read source →